Account statements as of June 30, 2020, are available via the Client Access link. We have also prepared the Q2 investor letter from Charles Buck, President and CEO, which includes preliminary performance information for Q2-2020.
We at United Church Funds are deeply concerned about what is happening throughout our nation. UCF is recommitting to using the proven and powerful strategy of responsible investing: investing to make a difference.
On June 22, Katie McCloskey, UCF Director of Social Responsibility, delivered a speech at the 2019 General Synod to introduce the Opioid Epidemic resolution. After her address, the resolution passed overwhelmingly.
United Church Funds is proud of its work to mitigate the opioid epidemic and produced the following report to inform General Synod 2019 delegates about its accomplishments in relation to the resolution of witness, which will be considered at General Synod.
United Church Funds has prepared the following report to inform General Synod 2019 delegates about UCF’s position on private prisons and the work for justice on the finance and support of private prison corporations.
United Church Funds continues its work to address fossil fuels investments and providing our stakeholders with options for investing without fossil fuels exposure.
UCF is celebrating the very successful campaign at pharmaceutical company Mallinckrodt, where a resolution that UCF sponsored on lobbying disclosures generated 79.7% support from the company’s shareholders.
Faith-based investors can support women’s socio-economic advancement through their investment portfolio. This article outlines a brief guideline to help get you started.
UCF joins other members of the Investor Alliance for Human Rights (IAHR) in celebrating the 70th anniversary of the UN Declaration on Human Rights. We are proud to be a member of the IAHR which interprets human rights to be one aspect of investors’ responsibility when making investment decisions.
At today’s annual shareholder meeting for Abbvie a first-time shareholder proposal questioning the links between executive compensation packages and drug price increases received a solid show of support from investors, signaling to the board of directors that this issue is key to investor confidence about the long-term sustainability of the company.